Corcept Therapeutics

Krystal Biotech

Arcellx

Avidity Biosciences

Crinetics Pharmaceuticals Inc

Alkermes

Immunovant Inc

Denali Therapeutics

Merus

PTC Therapeutics

ALPS Medical Breakthroughs ETF

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

Biotechnology has long been fertile territory for disruptive growth and innovation in the healthcare sector.  The ALPS Medical Breakthroughs ETF (SBIO) is one of the premier exchange traded funds to tap into that theme.

Turn Healthcare Breakthroughs into ETF Gains with This Fund

ARK Genomic Revolution Multi-Sector ETF

Biogen

Principal Healthcare Innovators Index ETF

Clover Health Investments

First Trust NYSE Arca Biotechnology Index Fund

Global X Genomics & Biotechnology ETF

Orphazyme A/S

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

Experienced investors know that talk of mergers and acquisitions activity is a near constant in the healthcare industry. Due to the sluggish pace of deal-making last year owing to the onset of the coronavirus pandemic, as well as a bright post-pandemic outlook for some pharmaceuticals companies, the back half of 2021 has the potential to [.

Post-Pandemic Healthcare Could Feature More Biotech M&A

Amplify Seymour Cannabis ETF

 Invesco S&P SmallCap Consumer Discretionary ETF

Invesco S&P SmallCap Energy ETF

Invesco S&P SmallCap Utilities & Communication Services ETF

We have presented five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month.

5 Small-Cap Sector ETFs Leading the Russell 2000 Rally

Virtus LifeSci Biotech Clinical Trials ETF

Invesco Dynamic Biotechnology & Genome ETF

SPDR S&P Biotech ETF

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

Biotechnology equities are slumping to start 2021, with the S&P Biotechnology Select Industry Index down 10% year-to-date. Mergers and acquisitions activity, which are typically vibrant in the biotech space, are also in a funk.

As Biotech Consolidation Heats up, ‘SBIO' Could Be a Winner

Amplify Treatments Testing & Advancements ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Healthcare Providers ETF

Invesco S&P 500 Equal Weight Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector outperformed in the past year due to the pandemic. Here are seven ETFs for your portfolio to look beyond Covid-19.

7 Health-Focused ETFs To Buy Now For the Post-Covid Future

Small cap biotech (SBIO) got so hot in the bull market period of 2011-2015 that it acquired a high-flying growth reputation closely associated with big tech and the FAANG stocks. This reputation, pairing biotech with big tech as similar growth sectors, has persisted in the mainstream financial media and in many people's minds.

SBIO: Don't Look Now, But Small Cap Biotech Is Actually A Relative Bargain Value Buy Again

Biotechnology sector-related exchange traded funds could stumble in the near-term as increased regulatory scrutiny weighs on drugmakers. Among the hardest hit areas of Tuesday, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) and SPDR S&P Biotech ETF (NYSEArca: XBI) both decreased 5.8% while the iShares Nasdaq Biotechnology ETF (IBB), the largest biotech-related ETF by assets, fell [.

Greater Regulatory Scrutiny Could Weigh on Biotech ETFs

 BlackRock Future Innovators ETF

Pacer US Small Cap Cash Cows 100 ETF

Invesco S&P SmallCap Value with Momentum ETF

We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.

5 Small-Cap ETFs at the Forefront of the 2021 Market Rally

Already off to a strong start in 2021, the ALPS Medical Breakthroughs ETF (SBIO) extended the good vibes by jumping 9% in the first full trading week of February. SBIO focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials.

Capture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO'

Clinical trials are of the utmost importance to biotechnology investors, but not all exchange traded funds adequately address the phenomenon. The ALPS Medical Breakthroughs ETF (SBIO) takes a different approach.

ALPS ‘SBIO' ETF: Trial Progress Meets Investing Success

Large cap biotechnology companies are flush with cash, and they're on the prowl for takeover targets, a scenario that could bode well for the ALPS Medical Breakthroughs ETF (SBIO). SBIO focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials.

Don't Miss Out on Rampant Biotech Mergers with the SBIO ETF

VanEck Vectors Biotech ETF

BioNTech SE

Loncar Cancer Immunotherapy ETF

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

Defiance Nasdaq Junior Biotechnology ETF

After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded funds that target the small and mid cap segments. According to Dealogic data, total deal volume for the drug industry reached $253 billion globally in [.

Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021

Invesco S&P SmallCap Materials ETF

Invesco S&P SmallCap Information Technology ETF

We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.

5 Small-Cap Sector ETFs Beating the Russell 2000

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Biotech ETF (SBIO) Hits a New 52-Week High

ALPS Clean Energy ETF

Alerian MLP ETF

ALPS Sector Dividend Dogs ETF

ALPS' Senior Investment Strategy Advisor Paul Baiocchi was early to the ETF party, becoming enamored with ETFs while attending business school in the mid-2000s. Doing stints at both ETF.com and Fidelity before joining up with ALPS, he has a unique sense of the ETF industry's past, present and future.

A View From The ALPS: An Evolving ETF Landscape (Podcast Transcript)

A View From The ALPS: An Evolving ETF Landscape (Podcast)

The Food and Drug Administration (FDA) appears likely to be active on the drug review front in the months, with COVID-19 in the way. Expect that activity could benefit exchange traded funds with exposure to small- and mid-cap biotechnology stocks, including the ALPS Medical Breakthroughs ETF (SBIO).

How Increased FDA Activity Can Benefit ETFs in Your Portfolio

Historically, biotechnology stocks and exchange traded funds thrive when elections are completed. And while the winner of the presidential race isn't crystal clear, the ALPS Medical Breakthroughs ETF (SBIO) notched a strong performance in the first trading day following Election Day.

More than Just COVID: Hot ETFs for Medical Breakthroughs

First Trust Mid Cap Value AlphaDEX Fund

Invesco KBW Regional Banking ETF

ProShares S&P MidCap 400 Dividend Aristocrats ETF

Amplify Junior Silver Miners ETF

The month of October was downbeat for Wall Street due to election uncertainty, failed stimulus talks, subdued tech earnings and rising coronavirus cases on the global front.

Can Small-Cap ETFs Keep Up the Winning Trend in November?

SPDR S&P Regional Banking ETF

Global X Lithium & Battery Tech ETF

AdvisorShares Pure US Cannabis ETF

VanEck Rare Earth/Strategic Metals ETF

Wall Street registered its first back-to-back monthly loss of this year, with Dow Jones closing out the worst month since March.

5 Sector ETFs That Showed Strength Despite the Worst October

With election year in the rearview mirror, 2021 could bring upside for biotechnology stocks and exchange traded funds if historical trends hold true to form. That would be a boon for the ALPS Medical Breakthroughs ETF (SBIO).

For 2021 Upside, Bet on the SBIO Biotech ETF

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biotechnology Index Fund were all up 1.4% at midday, dwarfing the 0.4% rise for the S&P 500.

News for ALPS Medical Breakthroughs ETF ETF (SBIO)